Peptic ulcer disease in patients with diabetes mellitus

Česká verzia

Authors: I. Tachecí ^1,2; J. Bureš ^1,2
Authors place of work: II. interní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc. ¹; Subkatedra gastroenterologie Lékařské fakulty UK Hradec Králové, vedoucí prof. MUDr. Jan Bureš, CSc. ²
Published in the journal: Vnitř Lék 2011; 57(4): 347-350
Category: 12th national Symposium diabetes, "Diabetes and Gastroenterology", Hradec Kralove, 4 to 5 June 2010

Summary

Peptic ulcer disease and diabetes mellitus are the serious chronic diseases with many medicals and socioeconomic consequences. Although the changes leading to the mucosal vulnerability and prolonged healing of ulcers were many times demonstrated in experiment, the clinical data does not confirmed explicit association of those diseases. The patients with diabetes mellitus are threatened by complications of peptic ulcer disease (bleeding, perforation) above all. The Helicobacter pylori prevalence is in diabetics higher, the results of eradication of Helicobacter pylori are unsatisfactory.

Key words:
diabetes mellitus – peptic ulcer disease – Helicobacter pylori

Zdroje

1. Srb T. Aktuální informace Ústavu zdravotnických informací a statistiky České republiky. 2010; 23.

2. Räihä I, Kemppainen H, Kaprio J et al. Lifestyle, stress, and genes in peptic ulcer disease: a nationwide twin cohort study. Arch Intern Med 1998; 158: 698–704.

3. Yoshitake S, Okada M, Kimura A et al. Contribution of major histocompatibility complex genes to susceptibility and resistance in Helicobacter pylori related diseases. Eur J Gastroenterol Hepatol 1999; 11: 875–880.

4. Bureš J, Kopáčová M, Koupil I et al. European Society for Primary Care Gastroenterology. Epidemiology of Helicobacter pylori infection in the Czech Republic. Helicobacter 2006; 11: 56–65.

5. Konturek PC, Brzozowski T, Burnat G et al. Gastric ulcer healing and stress-lesion preventive properties of pioglitazone are attenuated in diabetic rats. J Physiol Pharmacol 2010; 61: 429–436.

6. Brzozowska I, Targosz A, Sliwowski Z et al. Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (NO)-derivative of aspirin and cyclooxygenase (COX)-2 inhibitor. J Physiol Pharmacol 2004; 55: 773–790.

7. Harsch IA, Brzozowski T, Bazela K et al. Impaired gastric ulcer healing in diabetic rats: role of heat shock protein, growth factors, prostaglandins and proinflammatory cytokines. Eur J Pharmacol 2003; 481: 249–260.

8. Tashima K, Fujita A, Takeuchi K. Aggravation of ischemia/reperfusion-induced gastric lesions in streptozotocin-diabetic rats. Life Sci 2000; 67: 1707–1718.

9. Korolkiewicz RP, Tashima K, Fujita A et al. Exogenous insulin-like growth factor (IGF)-1 improves the impaired healing of gastric mucosal lesions in diabetic rats. Pharmacol Res 2000; 41: 221–229.

10. Takeuchi K, Takehara K, Tajima K et al. Impaired healing of gastric lesions in streptozotocin-induced diabetic rats: effect of basic fibroblast growth factor. J Pharmacol Exp Ther 1997; 281: 200–207.

11. Takehara K, Tashima K, Takeuchi K. Alterations in duodenal bicarbonate secretion and mucosal susceptibility to acid in diabetic rats. Gastroenterology 1997; 112: 418–428.

12. Sato T, Kitahara F, Nakamura T et al. Peptic ulcer in patients with diabetes mellitus. Nippon Rinsho 2002; 60: 1580–1584.

13. Wafula JM, Lule GN, Otieno CF et al. Upper gastrointestinal findings in diabetic outpatients at Kenyatta National Hospital, Nairobi. East Afr Med J 2002; 79: 232–236.

14. Aro P, Storskrubb T, Ronkainen J et al. Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. Am J Epidemiol 2006; 163: 1025–1034.

15. Lee CM, Huxley RR, Lam TH et al. Woodward M; Asia Pacific Cohort Studies Collaboration. Prevalence of diabetes mellitus and population attributable fractions for coronary heart disease and stroke mortality in the WHO South-East Asia and Western Pacific regions. Asia Pac J Clin Nutr 2007; 16: 187–192.

16. Arslan D, Kendirci M, Kurtoglu S et al. Helicobacter pylori infection in children with insulin dependent diabetes mellitus. J Pediatr Endocrinol Metab 2000; 13: 553–556.

17. Salardi S, Cacciari E, Menegatti M et al. Helicobacter pylori and type 1 diabetes mellitus in children. J Pediatr Gastroenterol Nutr 1999; 28: 307–309.

18. Gasbarrini A, Ojetti V, Pitocco D et al. Insulin-dependent diabetes mellitus affects eradication rate of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1999; 11: 713–716.

19. Gulcelik NE, Kaya E, Demirbas B et al. Helicobacter pylori prevalence in diabetic patients and its relationship with dyspepsia and autonomic neuropathy. J Endocrinol Invest 2005; 28: 214–217.

20. Devrajani BR, Shah SZ, Soomro AA et al. Type 2 diabetes mellitus: A risk factor for Helicobacter pylori infection: A hospital based case-control study. Int J Diabetes Dev Ctries 2010; 30: 22–26.

21. Bener A, Micallef R, Afifi M et al. Association between type 2 diabetes mellitus and Helicobacter pylori infection. Turk J Gastroenterol 2007; 18: 225–229.

22. Persico M, Suozzo R, De Seta M et al. Non-ulcer dyspepsia and Helicobacter pylori in type 2 diabetic patients: association with autonomic neuropathy. Diabetes Res Clin Pract 1996; 31: 87–92.

23. Quadri R, Rossi C, Catalfamo E et al. Helicobacter pylori infection in type 2 diabetic patients. Nutr Metab Cardiovasc Dis 2000; 10: 263–266.

24. Senturk O, Canturk Z, Cetinarslan B et al. Prevalence and comparisons of five different diagnostic methods for Helicobacter pylori in diabetic patients. Endocr Res 2001; 27: 179–189.

25. Anastasios R, Goritsas C, Papamihail C et al. Helicobacter pylori infection in diabetic patients: prevalence and endoscopic findings. Eur J Intern Med 2002; 13: 376.

26. Kozák R, Juhász E, Horvát G et al. Helicobacter pylori infection in diabetic patients. Orv Hetil 1999; 140: 993–995.

27. Xia HH, Talley NJ, Kam EP et al. Helicobacter pylori infection is not associated with diabetes mellitus, nor with upper gastrointestinal symptoms in diabetes mellitus. Am J Gastroenterol 2001; 96: 1039–1046.

28. Stanciu OG, Trifan A, Sfarti C et al. Helicobacter pylori infection in patients with diabetes mellitus. Rev Med Chir Soc Med Nat Iasi 2003; 107: 59–65.

29. Bureš J, Šmahelová A, Kopáčová M et al. Clinical importance of Helicobacter pylori infection in patients with diabetes mellitus. Vnitř Lék 2004; 50: 350–353.

30. Zelenkova J, Součková A, Kvapil M et al.Helicobacter pylori and diabetes mellitus. Čas Lék Čes 2002; 141: 575–577.

31. Kojecký V, Roubalík J, Bartoníková N. Helicobacter pylori in patients with diabetes mellitus. Vnitř Lék 1993; 39: 581–584.

32. Pietroiusti A, Giuliano M, Magrini A et al. Cytotoxin-associated gene A strains of Helicobacter pylori represent a risk factor for the development of microalbuminuria in type 2 diabetes. Diabetes Care 2006; 29: 1399–1401.

33. Boehme MW, Autschbach F, Ell C et al. Prevalence of silent gastric ulcer, erosions or severe acute gastritis in patients with type 2 diabetes mellitus – a cross-sectional study. Hepatogastroenterology 2007; 54: 643–648.

34. Gasbarrini A, Franceschi F, Gasbarrini G et al. Extraintestinal pathology associated with Helicobacter infection. Eur J Gastroenterol Hepatol 1997; 9: 231–233.

35. Ojetti V, Pitocco D, Ghirlanda G et al. Role of Helicobacter pylori infection in insulin-dependent diabetes mellitus. Minerva Med 2001; 92: 137–144.

36. Sargýn M, Uygur-Bayramicli O, Sargýn H et al. Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori. World J Gastroenterol 2003; 9: 1126–1128.

37. Ojetti V, Pitocco D, Bartolozzi F et al. High rate of Helicobacter pylori re-infection in patients affected by type 1 diabetes. Diabetes Care 2002; 25: 1485.

38. Ataseven H, Demir M, Gen R. Effect of sequential treatment as a first-line therapy for Helicobacter pylori eradication in patients with diabetes mellitus. South Med J 2010; 103: 988–992.

39. Weil J, Langman MJ, Wainwright P et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000; 46: 27–31.

40. Schimke K, Chubb SA, Davis WA et al. Antiplatelet therapy, Helicobacter pylori infection and complicated peptic ulcer disease in diabetes: the Fremantle Diabetes Study. Diabet Med 2009; 26: 70–75.